With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for spinocerebellar ataxia.

The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said ...

Dr. Meg Richards from Panalgo discusses how real-world data is unlocking advancements in drug safety during pregnancy.

Wall Street analysts have high expectations for datopotomab deruxtecan, which is part of a lucrative alliance between AstraZeneca and Daiichi and is in clinical testing for several cancer types.

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

Boston, MA – The much-anticipated RE•WORK AI in Healthcare & Pharma Summit is set to take place on November 13-14, 2024, at ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

It’s a real opportunity to reinforce hope and to start getting comfortable with the word ‘cure,” said a leader of the study, which tested Opdivo and Yervoy.

GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells faster and simpler than current methods.

Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.

The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple times and, according to an analyst, will lead to a restructuring of the ...

The funding will support mid-stage testing of a drug the company believes to have the potential to treat a range of neurodegenerative conditions.